American Association for Cancer Research
00085472can191302-sup-221219_2_supp_5623440_pb15th.pdf (652.9 kB)

Figure S3 from HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer

Download (652.9 kB)
journal contribution
posted on 2023-03-31, 03:45 authored by Takeshi Fukumoto, Nail Fatkhutdinov, Joseph A. Zundell, Evgenii N. Tcyganov, Timothy Nacarelli, Sergey Karakashev, Shuai Wu, Qin Liu, Dmitry I. Gabrilovich, Rugang Zhang

Figure S3 shows that the effects of HDAC6 inhibitor ACY1215 alone or in combination with anti-PD-L1 on tumor immune microenvironment and that the combination of HDAC6 inhibitor ACY1215 and anti-PD-L1 does not affect the body weight of the treated mice.



US Department of Defense

Ovarian Cancer Research Alliance



ARID1A, encoding a subunit of the SWI/SNF complex, is the most frequently mutated epigenetic regulator in human cancers and is mutated in more than 50% of ovarian clear cell carcinomas (OCCC), a disease that currently has no effective therapy. Inhibition of histone deacetylase 6 (HDAC6) suppresses the growth of ARID1A-mutated tumors and modulates tumor immune microenvironment. Here, we show that inhibition of HDAC6 synergizes with anti-PD-L1 immune checkpoint blockade in ARID1A-inactivated ovarian cancer. ARID1A directly repressed transcription of CD274, the gene encoding PD-L1. Reduced tumor burden and improved survival were observed in ARID1Aflox/flox/PIK3CAH1047R OCCC mice treated with the HDAC6 inhibitor ACY1215 and anti-PD-L1 immune checkpoint blockade as a result of activation and increased presence of IFNγ-positive CD8 T cells. We confirmed that the combined treatment limited tumor progression in a cytotoxic T-cell–dependent manner, as depletion of CD8+ T cells abrogated these antitumor effects. Together, these findings indicate that combined HDAC6 inhibition and immune checkpoint blockade represents a potential treatment strategy for ARID1A-mutated cancers. These findings offer a mechanistic rationale for combining epigenetic modulators and existing immunotherapeutic interventions against a disease that has been so far resistant to checkpoint blockade as a monotherapy.See related commentary by Prokunina-Olsson, p. 5476

Usage metrics

    Cancer Research



    Ref. manager